We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




PCR-Based Endometrial Cancer Detection Test to Prevent Missed Diagnoses

By LabMedica International staff writers
Posted on 31 Aug 2023

Endometrial cancer is the most frequently diagnosed gynecologic cancer. In 2020, around 417,367 individuals received an endometrial cancer diagnosis. One out 10 women experiencing abnormal bleeding during their lifetimes will need invasive specialist biopsy procedures to rule out endometrial cancer. Previous research has identified specific gene hypermethylation as a potential biomarker for endometrial cancer detection. This has now paved the way for a minimally invasive test that identifies methylated biomarkers, indicating gene repression linked to malignancy. By utilizing the widely accepted pap smear or HPV sampling approach, this molecular test offers huge potential as a supplementary tool for assisting in endometrial cancer diagnosis right at the clinic.

INEX Innovate (Singapore) has launched epiHERA, the company’s early endometrial cancer detection technology, powered by a cutting-edge PCR test that is designed to detect epigenetic changes in genes associated with the presence of endometrial cancer. The epiHERA testing process starts with a simple cervical swab, similar to the sample collection method employed in cervical cancer screening. Subsequent steps involve genomic DNA extraction and bisulfite conversion. The final phase of the test entails real-time PCR analysis, focusing on the hypermethylated CDO1 and CELF4 genes. This streamlined process takes about six hours to be completed.

epiHERA addresses a critical gap in existing diagnostics by promoting equitable access to testing for vulnerable women. Its innovative methodology streamlines sample collection, significantly reducing turnaround time from weeks to days. Leveraging the scalability of molecular PCR testing ensures widespread availability, thereby increasing epiHERA's impact in the field of women's health. epiHERA has shown promising results in validation studies. Researchers can now access epiHERA for validation within their unique population cohorts, facilitating diverse applications and a comprehensive understanding of its efficacy.

“The launch of epiHERA is a testament not only to a shift in endometrial cancer detection but also underscores INEX Innovate's unwavering dedication to innovative solutions that enable timely interventions and improved patient outcomes,” said Kane Black, CEO of INEX Innovate. “epiHERA is the latest test launched by our team as we continue our path to being Asia’s pre-eminent women’s life science platform, and has received significant interest from clinicians and lab operators in the region. The launch comes at an exciting time of growth for the company on the back of recent acquisitions in the area as we expand both technology pipelines and geographically across the region.”

Related Links:
INEX Innovate 

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.